<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106494</url>
  </required_header>
  <id_info>
    <org_study_id>C2013-01</org_study_id>
    <nct_id>NCT02106494</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC</brief_title>
  <official_title>A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study objective is to demonstrate the superiority of APF530 500 mg given
      subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a
      maximum of 16 mg) in the delayed-phase (&gt; 24-120 hours) complete response (CR) rate (defined
      as no emesis and no use of rescue medications) in subjects receiving highly emetogenic
      chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed Phase Complete Response (CR) Rate</measure>
    <time_frame>24 - 120 Hours</time_frame>
    <description>Percentage of Participants with no emesis and no rescue medication in patients receiving HEC in the delayed phase (24 to 120 hours) of CINV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Complete Response Rate</measure>
    <time_frame>0 - 120 Hours</time_frame>
    <description>To determine the effect of APF530 on complete response rates in the overall phase (0 to 120 hours) of CINV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Complete Control (CC) Rate</measure>
    <time_frame>24 - 120 Hours</time_frame>
    <description>To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the delayed phase (24 to 120 hours) of CINV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Complete Control Rate</measure>
    <time_frame>0 - 120 Hours</time_frame>
    <description>To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the overall phase (0 to 120 hours) of CINV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of No Emetic Episodes</measure>
    <time_frame>0 - 120 Hours</time_frame>
    <description>To determine the effect of APF530 on the rate of no emetic episodes (vomiting or retching) in the overall phase (0 to 120 hours) of CINV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">942</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>APF530 500 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron 0.15 mg/kg IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APF530</intervention_name>
    <arm_group_label>APF530 500 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <arm_group_label>ondansetron 0.15 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron placebo</intervention_name>
    <arm_group_label>APF530 500 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APF530 placebo</intervention_name>
    <arm_group_label>ondansetron 0.15 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <arm_group_label>APF530 500 mg SC</arm_group_label>
    <arm_group_label>ondansetron 0.15 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>APF530 500 mg SC</arm_group_label>
    <arm_group_label>ondansetron 0.15 mg/kg IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be males or nonpregnant females who are 18-87 years of age at the time
             of enrollment.

          -  Subjects must have histologically or cytologically confirmed malignant disease.

          -  Subjects must be undergoing treatment with a HEC regimen according to the 2011 ASCO
             CINV guidelines for further details on the emetogenic classifications of chemotherapy
             agents for this study).

          -  A life expectancy &gt; 6 months

          -  Subjects must be able to receive standardized doses of dexamethasone as required in
             the protocol for the prevention of emesis.

          -  Subjects must be characterized as having Eastern Cooperative Oncology Group (ECOG)
             performance status of 0 or 1.

          -  Subjects must have adequate bone marrow, kidney, and liver function.

          -  Subjects must be able to swallow oral medications (pills) without difficulty.

          -  Subjects must be entering the first cycle of their current chemotherapy regimen.

          -  Subjects must be willing and able to comply with all testing and requirements defined
             in the protocol.

          -  Subjects must be able to provide voluntary, written, informed consent to participate
             in this study and must be able to fully understand the study requirements.

          -  Female subjects cannot be pregnant and must be adequately protected from conception
             for the duration of study, using at least one form of contraception. It is recommended
             that females and female partners of male subjects remain adequately protected from
             conception during the study and for up to 1 year following study participation.

        Exclusion Criteria:

          -  Subject has a known hypersensitivity to granisetron or any 5-HT3 receptor antagonist.

          -  Subject has a history or presence of clinically significant abnormal 12-lead ECG or an
             ECG with QTc by Bazett's correction of &gt; 450 msec in men and &gt; 470 msec in women on
             the screening ECG.

          -  Subject has PR &gt; 240 msec, QRS &gt; 110 msec, or a history of prolongation of QT
             interval.

          -  Subject has a family history of long QT syndrome.

          -  Subject has a history of cardiac disease, including congenital long QT syndrome,
             angina, myocardial ischemia or infarction, congestive heart failure, myocarditis, or
             chest pain or dyspnea on exertion.

          -  Subject has an electrolyte disturbance, such as uncorrected hypokalemia/hyperkalemia,
             hypomagnesemia, or hypocalcemia.

          -  Subject has idiopathic cardiomyopathy, syncope, epilepsy, hypertrophic cardiomyopathy,
             or other clinically significant cardiac disease.

          -  Subject is pregnant or breast-feeding.

          -  Subject is planning to receive multiple-day chemotherapy.

          -  Subject has taken any of the following agents within 7 days prior to initiation of
             chemotherapy (the study): 5-HT3 receptor antagonists, phenothiazines, benzamides,
             domperidone, cannabinoids, or NK-1 receptor antagonist.

          -  Subject has taken any benzodiazepine within 1 day (24 hours) prior to initiation of
             chemotherapy (the study).

          -  Subject is scheduled to receive any other chemotherapeutic agent from Day 2 through
             Day 6.

          -  Subject is scheduled to receive any radiation therapy to the abdomen or pelvis from
             Day -5 through Day 6.

          -  Subject has received systemic corticosteroids or sedative antihistamines within 72
             hours of Day 1 of the study, except as premedication for chemotherapy (e.g., taxanes,
             pemetrexed).

          -  Subject has symptomatic primary or metastatic central nervous system (CNS) disease.

          -  Subject has ongoing vomiting, retching, or nausea caused by any etiology, or has a
             history of anticipatory nausea and vomiting.

          -  Subject has vomited and/or has had dry heaves or retching within 24 hours prior to the
             start of HEC on Day 1.

          -  Subject is NOT able to swallow oral medications (pills) without difficulty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gelder, MD</last_name>
    <role>Study Director</role>
    <affiliation>Heron Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HAL</name>
      <address>
        <city>Pheonix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Medical Center</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Research</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Research</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Oncology</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, Wilks ST, Schwartzberg LS, Cooper W, Mosier MC, Payne JY, Klepper MJ, Vacirca JL. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol. 2016 Jun;12(12):1469-81. doi: 10.2217/fon-2016-0070. Epub 2016 Mar 21.</citation>
    <PMID>26997579</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <results_first_submitted>September 1, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2016</results_first_posted>
  <disposition_first_submitted>July 7, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 11, 2016</disposition_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Highly emetogenic chemotherapy (HEC)</keyword>
  <keyword>Chemotherapy-Induced Nausea and Vomiting (CINV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients receiving highly emetogenic chemotherapy were stratified by cisplatin and randomized 1:1 to one of two treatment arms</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>APF530 + Fosaprepitant + Dexamethasone</title>
          <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for Ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
        </group>
        <group group_id="P2">
          <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
          <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC+ Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="471"/>
                <participants group_id="P2" count="471"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="459"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Efficacy Population</title>
              <participants_list>
                <participants group_id="P1" count="450"/>
                <participants group_id="P2" count="452"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="446"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with a histologically or cytologically confirmed cancer diagnosis were scheduled to receive first cycle single day highly emetogenic chemotherapy (HEC)</population>
      <group_list>
        <group group_id="B1">
          <title>APF530 + Fosaprepitant + Dexamethasone</title>
          <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for ondansetron IV + Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 - Dexamethasone 8 mg PO QD
Days 3 and 4 - Dexamethasone 8 mg PO BID</description>
        </group>
        <group group_id="B2">
          <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
          <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC + Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 - Dexamethasone 8 mg PO QD
Days 3 and 4 - Dexamethasone 8 mg PO BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="450"/>
            <count group_id="B2" value="452"/>
            <count group_id="B3" value="902"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="667"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="11.74"/>
                    <measurement group_id="B2" value="55.6" spread="11.94"/>
                    <measurement group_id="B3" value="55.65" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="373"/>
                    <measurement group_id="B3" value="731"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Delayed Phase Complete Response (CR) Rate</title>
        <description>Percentage of Participants with no emesis and no rescue medication in patients receiving HEC in the delayed phase (24 to 120 hours) of CINV.</description>
        <time_frame>24 - 120 Hours</time_frame>
        <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>APF530 + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 - Dexamethasone 8 mg PO QD
Days 3 and 4 - Dexamethasone 8 mg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC + Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 - Dexamethasone 8 mg PO QD
Days 3 and 4 - Dexamethasone 8 mg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Phase Complete Response (CR) Rate</title>
          <description>Percentage of Participants with no emesis and no rescue medication in patients receiving HEC in the delayed phase (24 to 120 hours) of CINV.</description>
          <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Complete Response Rate</title>
        <description>To determine the effect of APF530 on complete response rates in the overall phase (0 to 120 hours) of CINV.</description>
        <time_frame>0 - 120 Hours</time_frame>
        <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>APF530 + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for Ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC+ Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Complete Response Rate</title>
          <description>To determine the effect of APF530 on complete response rates in the overall phase (0 to 120 hours) of CINV.</description>
          <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4"/>
                    <measurement group_id="O2" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Complete Control (CC) Rate</title>
        <description>To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the delayed phase (24 to 120 hours) of CINV.</description>
        <time_frame>24 - 120 Hours</time_frame>
        <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>APF530 + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for Ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC+ Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Complete Control (CC) Rate</title>
          <description>To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the delayed phase (24 to 120 hours) of CINV.</description>
          <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Complete Control Rate</title>
        <description>To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the overall phase (0 to 120 hours) of CINV.</description>
        <time_frame>0 - 120 Hours</time_frame>
        <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>APF530 + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for Ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC+ Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Complete Control Rate</title>
          <description>To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the overall phase (0 to 120 hours) of CINV.</description>
          <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                    <measurement group_id="O2" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of No Emetic Episodes</title>
        <description>To determine the effect of APF530 on the rate of no emetic episodes (vomiting or retching) in the overall phase (0 to 120 hours) of CINV.</description>
        <time_frame>0 - 120 Hours</time_frame>
        <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>APF530 + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for Ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
          <group group_id="O2">
            <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
            <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC+ Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 – Dexamethasone 8 mg PO QD
Days 3 and 4 – Dexamethasone 8 mg PO BID</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of No Emetic Episodes</title>
          <description>To determine the effect of APF530 on the rate of no emetic episodes (vomiting or retching) in the overall phase (0 to 120 hours) of CINV.</description>
          <population>Modified Intent to Treat (mITT) - all subjects in the randomized population who receive study drug and a HEC regimen and have post-baseline efficacy data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2"/>
                    <measurement group_id="O2" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The reporting period for AEs was the period starting from the time of informed consent signature until 30±3 days after study drug administration (Day 1 of chemotherapy cycle). Treatment-emergent AEs were those that either began or increased in severity after administration of study drug and within 8 days of study drug administration.</time_frame>
      <desc>Events other than injection site reactions were collected by non-systematic assessment. Injection site reactions were also collected via patient diaries.</desc>
      <group_list>
        <group group_id="E1">
          <title>APF530 + Fosaprepitant + Dexamethasone</title>
          <description>Day 1 - Single SC dose of APF530 500 mg (10 mg granisetron) + Placebo for ondansetron IV+ Fosaprepitant 150 mg IV+ Dexamethasone 12 mg IV
Day 2 - Dexamethasone 8 mg PO QD
Days 3 and 4 - Dexamethasone 8 mg PO BID</description>
        </group>
        <group group_id="E2">
          <title>Ondansetron + Fosaprepitant + Dexamethasone</title>
          <description>Day 1 - Single IV dose of Ondansetron 0.15 mg/kg (up to a maximum of 16 mg) + Placebo for APF530 SC+ Fosaprepitant 150 mg IV + Dexamethasone 12 mg IV
Day 2 - Dexamethasone 8 mg PO QD
Days 3 and 4 - Dexamethasone 8 mg PO BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febria Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mouth Haemmorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Breast Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemical Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Traumatic Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="411" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="407" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A period of 60 working days for presentational material and abstracts and 90 days for manuscripts is permitted for the sponsor's review. The sponsor can request modifications of any manuscript or other materials to be published or presented. The sponsor can also request additional time to obtain additional patent protection or take such other measures to establish and preserve its intellectual property and proprietary rights before publishing information from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Geller, M.D.</name_or_title>
      <organization>Heron Therapeutics</organization>
      <phone>650-366-2626</phone>
      <email>rgeller@herontx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

